New combo attack on tough lung cancers
NCT ID NCT02638090
Summary
This study is testing if combining two existing cancer drugs, pembrolizumab and vorinostat, is safe and works better than pembrolizumab alone for people with advanced lung cancer that has spread. It will involve about 120 adults whose cancer has progressed after at least one prior treatment. The goal is to see if this combination can better control the cancer's growth and extend the time before it gets worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.